Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01061684
Other study ID # NAFLD Pediatric Database 2
Secondary ID U01DK061730
Status Completed
Phase
First received
Last updated
Start date January 20, 2010
Est. completion date May 31, 2020

Study information

Verified date February 2022
Source Johns Hopkins Bloomberg School of Public Health
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The NAFLD Database 2 will recruit at least 650 new pediatric participants with liver biopsies and contemporaneous biosamples, and will also invite pediatric participants from the prior NAFLD Database and TONIC trial (50 with a recent biopsy and 150 without a contemporaneous biopsy) to enroll in the NAFLD Pediatric Database 2 study. Combining the new and continuing participants leads to a recruitment goal for the pediatric Database 2 of 850 pediatric participants during the enrollment period.


Description:

All the new pediatric participants will have had a liver biopsy within 120 days prior to enrollment coupled with contemporaneous biosamples within 90 days prior to enrollment and up to 90 days before or 4-90 days after the biopsy. We estimate that at least 50 of the continuing pediatric participants will be due for a standard of care liver biopsy at the time of their enrollment into the pediatric Database 2 study, and will, as a result, also have a liver biopsy and contemporaneous biosamples.


Recruitment information / eligibility

Status Completed
Enrollment 969
Est. completion date May 31, 2020
Est. primary completion date May 31, 2020
Accepts healthy volunteers No
Gender All
Age group 2 Years to 17 Years
Eligibility Inclusion Criteria: - Continuing participants: - Previously enrolled in the NAFLD Database study or TONIC trial - Age at least 2 years and not older than 17 years during the consent process - Willingness to continue to be followed for up to 4 years - Ability and willingness to give written, informed parental consent and child assent, per local IRB guidelines, to be enrolled into the pediatric Database 2 study - New participants: - Age at least 2 years of age and not older than 17 years during the consent process - Willingness to be followed for up to 4 years - Ability and willingness to give written, informed parent consent and child assent to be enrolled into the pediatric Database 2 study - Minimal or no alcohol use history consistent with NAFLD - Having undergone a liver biopsy that is obtained within 120 days of enrollment - Collection of biosamples (serum, plasma, DNA, and, if available, liver tissue) within 90 days prior to enrollment and 0-90 days before or 4-90 days after the standard of care liver biopsy Exclusion Criteria: - Total parenteral nutrition for more than 1 month within a 6 month period before baseline liver biopsy - Short bowel syndrome - History of gastric or jejunoileal bypass preceding the diagnosis of NAFLD. Bariatric surgery performed following enrollment is not exclusionary. Liver biopsies obtained during bariatric surgery cannot be used for enrollment because of the associated surgical or anesthetic acute changes and the weight loss efforts that precede bariatric surgery - History of biliopancreatic diversion - Evidence of advanced liver disease defined as a Child-Pugh-Turcotte score equal to or greater than 10 - Evidence of chronic hepatitis B as marked by the presence of HBsAg in serum (participants with isolated antibody to hepatitis B core antigen, anti-HBc total, are not excluded) - Evidence of chronic hepatitis C as marked by the presence of anti-HCV or HCV RNA in serum - Low alpha-1-antitrypsin level and ZZ phenotype (both determined at the discretion of the investigator) - Wilson's disease - Known glycogen storage disease - Known dysbetalipoproteinemia - Known phenotypic hemochromatosis (HII greater than 1.9 or removal of more than 4 g of iron by phlebotomy) - Prominent bile duct injury (florid duct lesions or periductal sclerosis) or bile duct paucity - Chronic cholestasis - Vascular lesions (vasculitis, cardiac sclerosis, acute or chronic Budd-Chiari, hepatoportal sclerosis, peliosis) - Iron overload greater than 3+ - Zones of confluent necrosis, infarction, massive or sub-massive, pan-acinar necrosis - Multiple epithelioid granulomas - Congenital hepatic fibrosis - Cystic fibrosis - Polycystic liver disease - Other metabolic or congenital liver disease - Evidence of systemic infectious disease - Known HIV positive - Disseminated or advanced malignancy - Concomitant severe underlying systemic illness that in the opinion of the investigator would interfere with completion of follow-up - Active drug use or dependence that, in the opinion of the study investigator, would interfere with adherence to study requirements - Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of study - Inability for parent to provide informed consent and child 8 years or greater to give assent

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Emory University Atlanta Georgia
United States Johns Hopkins University Baltimore Maryland
United States University at Buffalo-Women and Children's Hospital of Buffalo Buffalo New York
United States Ann & Robert H. Lurie Children's Hospital of Chicago (NWU) Chicago Illinois
United States Cincinnati Children's Hospital Medical Center Cincinnati Ohio
United States Texas Children's Hospital Houston Texas
United States Riley Hospital for Children Indianapolis Indiana
United States Columbia University New York New York
United States St. Louis University Saint Louis Missouri
United States University of California, San Diego San Diego California
United States University of California, San Francisco San Francisco California
United States Seattle Children's Hospital- UW Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins Bloomberg School of Public Health National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Liver histology scores Liver histology scores (derived from central reading of liver biopsy at entry, standard of care biopsy done during screening or follow-up, or liver biopsy obtained for the TONIC trial) varies
See also
  Status Clinical Trial Phase
Completed NCT02798861 - Controlled Attenuation Parameter (CAP) in Liver Allografts
Completed NCT01968395 - Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Phase 4
Completed NCT01437969 - Pharmacogenomics Study on IL28B Genetic Variants in Italian Patients With HCV Infection naïve to Treatment.
Recruiting NCT00155376 - Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Phase 4
Recruiting NCT00172705 - Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique N/A
Completed NCT04185454 - Estimation of Minimum Efficacy Daily Dose of Jarlsberg Cheese N/A
Completed NCT02506335 - Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease Early Phase 1
Completed NCT02520609 - Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Completed NCT02306018 - Evaluation of a New Calibrated Pulse Wave Analysis Method(EV1000™/volumeView™) for Cardiac Output Monitoring in Adult Liver Transplantation N/A
Completed NCT01970904 - Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients N/A
Completed NCT01988753 - Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Terminated NCT00741117 - Conjugated Hyperbilirubinemia and Pulse Oximetry N/A
Enrolling by invitation NCT01483248 - Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis Phase 1/Phase 2
Completed NCT00245830 - Ischemic Preconditioning of Liver in Cadaver Donors N/A
Completed NCT00074386 - Kidney and Liver Transplantation in People With HIV N/A
Completed NCT02329821 - Change of Lactate Concentration During Hartmann Solution Infusion for Hepatic Resection N/A
Completed NCT01650181 - Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Phase 4
Completed NCT01303549 - Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients Phase 4
Completed NCT00799851 - A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices Phase 4
Completed NCT00058890 - Gabapentin to Treat Itch in Patients With Liver Disease Phase 3